Navigation Links
Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
Date:6/2/2008

o irinotecan, NKTR-102 may prove to be a more powerful and tolerable anti-tumor agent. Preclinical studies show that treatment with NKTR-102 results in significant suppression of tumor growth in an irinotecan-resistant mouse colorectal tumor model and in similar models of breast and lung cancer. Administration of NKTR-102 in an animal model also results in a markedly improved time-concentration profile for SN38, the active metabolite of irinotecan, as compared to treatment with irinotecan.

Nektar PEGylation technology can enhance the properties of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It can also be used to modify pharmaceutical agents to preferentially target certain systems within the body. It is a technique in which non-toxic polyethylene glycol (PEG) polymers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs. Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including UCB's Cimzia(R) for Crohn's Disease, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled eight approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance. '/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a ... announced today,that Weidong Yin, Chairman, President & ... to be one of 18 nominees for ... CCTV,s Economic Man-of-the-Year is the country,s ... to as the "Oscar Award of the,Chinese ...
(Date:12/15/2009)... SAN DIEGO, Dec. 15 Accumetrics, Inc., ... first rapid and easy-to-use diagnostic system for measuring ... that 2009 included a doubling in the number ... as positive medical community support, and significant capital ... ,, In 2009, the company continued its ...
(Date:12/15/2009)... -- OBP Medical Inc. declares victory in the ... in hospitals. ,, Doctors at Newton-Wellesley Hospital in ... OBP Medical,s Under Johnnies(TM) on patients, comfort and ... survey is comparing patients, perception of comfort, privacy ... Under Johnnies(TM) against the traditional hospital gown and ...
Breaking Medicine Technology:Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 2Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 3Accumetrics Closes 2009 with Positive Outlook 2Accumetrics Closes 2009 with Positive Outlook 3Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc. 2MDA Cancels Remainder of Nationwide Summer Camp Program to Protect Children From Swine Flu 49534 1MDA Cancels Remainder of Nationwide Summer Camp Program to Protect Children From Swine Flu 49534 2Isolagen Inc Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion 12713 1Isolagen Inc Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion 12713 2Isolagen Inc Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion 12713 3Americans United for Life 3A Obamas Disbanding Bioethics Council Raises Troubling Questions 12712 1Americans United for Life 3A Obamas Disbanding Bioethics Council Raises Troubling Questions 12712 2
... March 9 In response to the President,s actions ... David Zanotti, CEO of the American Policy Roundtable and ... Roundtable, issued the following statement:"The President,s policy is very ... in the realm of autologous stem cell research. ...
... Treatment Relieves Pain From Herniated Disks; Pain and ... Fewer Complications, Shorter Recovery TimeSAN DIEGO, March 9 ... and effectively uses oxygen/ozone to relieve the pain ... States in the next few years, predict researchers ...
Other Medicine Technology:Oh, My Aching Back: Give Me a Shot of Ozone 2Oh, My Aching Back: Give Me a Shot of Ozone 3Oh, My Aching Back: Give Me a Shot of Ozone 4Oh, My Aching Back: Give Me a Shot of Ozone 5
(Date:12/15/2009)... Now that Physicians cannot bill Medicare for consultations how will ... explains how in easy to understand terms. , ... ... On January 1, 2010 Medicare will eliminate consultation codes. ... reimbursement when a patient is seen for a medical consultation, ...
(Date:12/15/2009)... as Henry Ford Health System Joins the influx of Healthcare ... ... Hazlet, N.J. (PRWEB) December 15, 2009 ... talent acquisition solutions , announced today that Henry Ford Health ... support its talent management needs. Henry Ford joins more than ...
(Date:12/15/2009)... new report titled, “Incontinence Devices Markets Worldwide.” The report ... and manage urinary incontinence. , ... ... to announce the release of a new report titled, “Incontinence ... for clinical devices used to treat and manage urinary incontinence., ...
(Date:12/15/2009)... DALLAS Dec. 15, 2009 UT Southwestern ... account to date of the unique observable characteristics ... aging syndrome. , The findings, reported online and ... of Clinical Endocrinology and Metabolism, suggest that ... be lumped together with those diagnosed with two ...
(Date:12/14/2009)... and NaturalFill™ revolutionary new liposuction and fat transfer treatments can ... all in one minimally invasive treatment. , ... ... AQUALIPO™ and NaturalFill™ can remove excess fat from the abdomen ... people slim down, reduce facial wrinkling and enhance lips all ...
Breaking Medicine News(10 mins):Health News:Medicare Eliminates Consultation Codes for Doctors 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 3Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 4Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 2Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 3Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3
... Research findings and innovative approaches offer the promise of ... living with type 1 diabetes, according to researchers at ... in Washington D.C. , Type 1 diabetes is an ... beta cells in the pancreas. It renders people ...
... are increasingly wired, survey finds , , WEDNESDAY, June 18 (HealthDay ... the wave of the future in health care and communication, ... technology, a new survey finds. , "When you use ... few physicians appear to have one," said lead study author ...
... ... Health Concerns, NEWBURYPORT, Mass., June ... TIME.com as,one of the best Web Sites in 2008 for its ... simple quizzes, "Ask the,Therapist" area, and prescription rating sections as reasons ...
... The following is a,statement from Larry Minnix, AAHSA ... for nursing homes:, "AAHSA believes there should ... the non-existent. Through Quality First, we have for ... based on,reliable quality information that the public can ...
... School,Health Association, the National Association of Secondary School ... together to create,one voice to urge Congress to ... Control Act, which would give the FDA authority ... each formed to assist the Nation,s youth,agree that ...
... Hologic, Inc.,(Nasdaq: HOLX ) today announced that Glenn ... 2nd Annual Healthcare Conference being,held June 24 - 26, ... NY., Interested parties are invited to listen to ... June 25, 2008, at 12:30 PM.,Eastern Time on the ...
Other Medicine News:Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 3Health News:Doctors Slow to Embrace Electronic Medical Records 2Health News:Doctors Slow to Embrace Electronic Medical Records 3Health News:Psych Central Selected by TIME Magazine as Top 50 Web Site in 2008 for Its Top Mental Health Content and Social Media Platform 2Health News:AAHSA Statement on Nursing Home Rating System 2Health News:Major Associations Band Together to Urge Congressional Action on Tobacco Legislation 2Health News:Hologic to Present at the Jefferies 2nd Annual Healthcare Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: